The Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications
2 In TRIUMPH-2, all three studied doses of retatrutide (4 mg, 9 mg, and 12 mg) delivered substantial weight loss and improved glycemic control at 80 weeks in adults with type 2 diabetes and obesity or overweight
(2021) GLP-1 receptor agonist-based and cardiovascular risk: a review of mechanisms Muller, Neerav et al
Common Pitfalls and How to Sidestep Them Our team has consulted on thousands of research projects, and we've seen the same handful of mistakes derail otherwise promising work
As part of ongoing patient assessment, healthcare providers should also ensure their patient is being treated with the optimum dose that achieves the best balance between efficacy, tolerability and acceptability [125]
Most importantly, we will learn what they knew about the risks when they failed to warn of stomach paralysis and intestinal blockage